Go Pro
NASDAQ:BRTX

Biorestorative Therapies (BRTX) Stock Price, News & Analysis

Biorestorative Therapies logo
$0.14 -0.06 (-28.76%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$0.15 +0.00 (+2.30%)
As of 07:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Biorestorative Therapies Stock (NASDAQ:BRTX)

Advanced

Key Stats

Today's Range
$0.14
$0.18
50-Day Range
$0.14
$0.40
52-Week Range
$0.14
$1.73
Volume
3.50 million shs
Average Volume
225,649 shs
Market Capitalization
$3.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy. Biorestorative Therapies’ candidate has completed early-stage clinical evaluation and is advancing through planned trials to assess safety and efficacy in reducing the duration and severity of oral mucositis. Preclinical studies have also been conducted to explore additional indications, including inflammatory and degenerative conditions.

Headquartered in Malvern, Pennsylvania, Biorestorative Therapies manages its research, manufacturing and clinical development activities in the United States. The company works with clinical research organizations and academic centers to support its ongoing trials and maintains a leadership team with experience spanning cell therapy, clinical development and regulatory affairs. Biorestorative Therapies continues to pursue partnerships to expand its pipeline and accelerate the path to potential regulatory approval.

AI Generated. May Contain Errors.

Biorestorative Therapies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
17th Percentile Overall Score

BRTX MarketRank™: 

Biorestorative Therapies scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Biorestorative Therapies has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Biorestorative Therapies has only been the subject of 1 research reports in the past 90 days.

  • Read more about Biorestorative Therapies' stock forecast and price target.
  • Earnings Growth

    Earnings for Biorestorative Therapies are expected to grow in the coming year, from ($0.66) to ($0.52) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biorestorative Therapies is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biorestorative Therapies is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Biorestorative Therapies has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Biorestorative Therapies' valuation and earnings.
  • Percentage of Shares Shorted

    0.45% of the float of Biorestorative Therapies has been sold short.
  • Short Interest Ratio / Days to Cover

    Biorestorative Therapies has a short interest ratio ("days to cover") of 0.33, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Biorestorative Therapies has recently decreased by 78.51%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Biorestorative Therapies does not currently pay a dividend.

  • Dividend Growth

    Biorestorative Therapies does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Biorestorative Therapies this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for BRTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Biorestorative Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Biorestorative Therapies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.60% of the stock of Biorestorative Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    69.38% of the stock of Biorestorative Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Biorestorative Therapies' insider trading history.
Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biorestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BRTX Stock News Headlines

BioRestorative Therapies Announces Reverse Stock Split
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you make with it. Using the 4% rule as a benchmark, that balance could translate to about $100,000 in year one, adjusted upward for inflation each year after. But the 4% rule has potential downsides and may not fit every portfolio. A financial advisor can help size and structure a retirement budget around your income sources, taxes, and goals. SmartAsset's free quiz matches nearly 50,000 people each month with vetted fiduciary advisors.tc pixel
See More Headlines

BRTX Stock Analysis - Frequently Asked Questions

Biorestorative Therapies' stock was trading at $1.1750 at the beginning of 2026. Since then, BRTX shares have decreased by 87.8% and is now trading at $0.1437.

Biorestorative Therapies, Inc. (NASDAQ:BRTX) issued its quarterly earnings results on Thursday, May, 14th. The company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.01. The firm earned $0.02 million during the quarter, compared to analyst estimates of $0.31 million. Biorestorative Therapies had a negative trailing twelve-month return on equity of 508.42% and a negative net margin of 3,088.27%.

Shares of Biorestorative Therapies reverse split on Wednesday, October 27th 2021.The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

Biorestorative Therapies' board authorized a stock buyback plan on Tuesday, June 17th 2025, which authorizes the company to repurchase $2,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 15.9% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board believes its shares are undervalued.

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biorestorative Therapies investors own include Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), NVIDIA (NVDA), American Graphite Technologies (AGIN).

Company Calendar

Last Earnings
5/14/2026
Today
9/04/2026
Next Earnings (Estimated)
9/08/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BRTX
Previous Symbol
OTCMKTS:BRTX
CIK
1505497
Fax
N/A
Employees
7
Year Founded
1997

Profitability

EPS (Trailing Twelve Months)
($1.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.24 million
Net Margins
-3,088.27%
Pretax Margin
-3,088.27%
Return on Equity
-508.42%
Return on Assets
-230.94%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.35
Quick Ratio
2.35

Sales & Book Value

Annual Sales
$360 thousand
Price / Sales
10.17
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.04 per share
Price / Book
3.59

Miscellaneous

Outstanding Shares
25,480,000
Free Float
22,013,000
Market Cap
$3.66 million
Optionable
Not Optionable
Beta
0.83

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:BRTX) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners